

# Digital Diagnostics

## Company Overview



### About Digital Diagnostics

Digital Diagnostics is a leading digital health company that uses autonomous AI to increase access to healthcare and lower its cost.

Founded on bioethical principles, the company builds its unique autonomous AI algorithms to make medical decisions without human oversight. Thereby specialty diagnostics are available where the patient already is, including primary care and retail settings.

Focused on improving population health, its AI algorithms minimize bias, and democratize access for underserved rural and minority populations to the highest quality care. Uniquely, Digital Diagnostics assumes liability for the performance of its AI algorithms.

### Our Products

LumineticsCore™ (formerly IDx-DR), is an FDA De Novo Authorized autonomous AI for use at the front lines of care to diagnose diabetic retinopathy (including macular edema).

#### LumineticsCore™: FDA-cleared autonomous AI

- Enables non-eye care providers to administer a diabetic retinopathy exam
- No specialist overread and no telemedicine required
- Completed by staff member with minimal training
- Immediate diagnostic results at the point-of-care

### At A Glance

**Company Name:** Digital Diagnostics

**Headquarters:** Coralville, IA U.S.

**Founded:** 2010

**Employees:** 100+

**Mission:** To benefit patients by transforming the accessibility, affordability, equity, and quality of global healthcare through the application of technology in the medical diagnosis and treatment process.

**Founder and Executive Chairman:**

Dr. Michael D. Abramoff

**Co-Founder, CEO :** John Bertrand

**Co-Founder, President, COO:** Seth Rainford

**Strategic Investors:** 8VC, Optum Ventures, Alpha Edison, Heritage Provider Network, KKR, Cedar Pine, Kinderhook, Optum Ventures, OSF Ventures, Gundersen Health System, Edward – Elmhurst Health Venture Capital, University of Iowa

- System includes all components needed for easy placement in retail and primary care clinics:
  - A smart robotic retinal camera
  - Highly accurate AI-based diagnostic algorithm
  - Interactive AI to guide the operator
  - Easy to use operator interface
  - Comprehensive user training program

## Digital Diagnostics Timeline

- » **2010:** Digital Diagnostics founded by Dr. Michael Abramoff, a retina specialist, computer engineer, and neuroscientist
- » **January 2017:** Digital Diagnostics launches a prospective, pre-registered clinical trial to test the safety, efficacy, and equity of LumineticsCore in primary care settings
- » **February 2018:** LumineticsCore receives “Breakthrough Device” designation from the FDA
- » **April 2018:** LumineticCore granted first FDA authorization for an autonomous AI diagnostic in any field of medicine
- » **August 2018:** Results of LumineticsCore clinical trial published in Nature Digital Medicine
- » **September 2018:** Digital Diagnostics secures \$33 million in venture capital funding to develop more diagnostic systems for its AI product suite
- » **February 2019:** LumineticsCore adoption expands to include endocrinology clinics, internal medicine clinics, diabetes education centers, and more
- » **June 2019:** The AMA’s CPT Editorial Panel accepts a new category 1 CPT code facilitating reimbursement of the LumineticsCore exam
- » **November 2019:** LumineticsCore launches in retail health
- » **December 2019:** ADA includes FDA-authorized AI in 2020 Standards of Medical Care in Diabetes
- » **July 2020:** NCQA publicly clarifies that LumineticsCore meets the criteria for HEDIS to close the eye exam for people with diabetes care gap
- » **August 2020:** Digital Diagnostics acquires 3Derm Systems Inc. of Boston, MA
- » **June 2021:** Digital Diagnostics and Orbis International announce study to help save sight in Bangladesh
- » **March 2022:** Digital Diagnostics and Baxter Int. announce new partnership
- » **July 2022:** Digital Diagnostics, Kingdom of Saudi Arabia sign intent to provide preventative healthcare to 35M with diabetes
- » **August 2022:** Digital Diagnostics secures \$75 million in Series B funding round led by KKR